Kiyatec, a leader in functional oncology testing with its proprietary 3D Predict™ platform, today announced it has closed a strategic investment round led by MBD, a South Korea-based technology leader. This new investment solidifies a strategic commercial partnership aimed at leveraging MBD’s automated platform technology to rapidly scale Kiyatec’s U.S.

Kiyatec是一家在功能性肿瘤检测领域领先的公司，拥有其专有的3D Predict™平台，今天宣布已完成一轮由韩国技术领导者MBD领投的战略投资。这项新投资巩固了旨在利用MBD的自动化平台技术快速扩展Kiyatec在美国的战略商业合作伙伴关系。

testing capabilities and accelerate the launch of its diagnostic panels for multiple cancer types along with new AI tools..

测试能力，并加速推出其针对多种癌症类型的诊断面板及新的AI工具。

The partnership represents a significant step in Kiyatec’s mission to provide clinicians with essential drug response data for cancer patients worldwide. MBD’s state-of-the-art automation will be integrated into Kiyatec’s CLIA/CAP laboratory operations in Greenville, SC, dramatically enhancing throughput and quality control as the company expands its commercial footprint..

该合作伙伴关系代表着Kiyatec在为全球癌症患者提供临床医生所需药物反应数据的使命中迈出了重要一步。MBD的先进自动化技术将被整合到Kiyatec位于南卡罗来纳州格林维尔的CLIA/CAP实验室运营中，随着公司扩展其商业版图，此举将大幅提升样本处理能力和质量控制。

'This strategic investment marks a pivotal moment for Kiyatec,' said Eric Perreault, CEO of Kiyatec. 'MBD is not just a financial partner; they are a technological force multiplier. By integrating their advanced automated platform, we can immediately enhance our scale, reduce turnaround times, and solidify our path to providing drug response results to thousands of glioblastoma patients.

“这项战略投资标志着 Kiyatec 的一个关键转折点，”Kiyatec 首席执行官 Eric Perreault 表示。“MBD 不仅仅是一个财务合作伙伴；他们是一个技术力量倍增器。通过整合他们先进的自动化平台，我们可以立即扩大规模、缩短周转时间，并巩固我们为数千名胶质母细胞瘤患者提供药物反应结果的道路。”

Crucially, this partnership will accelerate the validation and launch of our testing panels for other high-incidence cancers, including ovarian, breast, and non-small cell lung cancer.'.

关键的是，这一合作将加速我们针对其他高发癌症（包括卵巢癌、乳腺癌和非小细胞肺癌）的检测面板的验证和上市。

The immediate integration of MBD's technology is designed to optimize Kiyatec's operational efficiency, enabling the company to meet the growing demand from physicians across the United States.

MBD技术的立即整合旨在优化Kiyatec的运营效率，使公司能够满足美国各地医生日益增长的需求。

Bosung Ku, CEO of MBD, commented on the partnership: 'Kiyatec’s 3D Predict technology and its compelling clinical performance data—particularly in glioblastoma—represent the future of personalized oncology. Our investment reflects our firm commitment to supporting global leaders who are advancing patient care.

MBD首席执行官具保成在谈到此次合作时表示：“Kiyatec的3D Predict技术及其令人信服的临床表现数据——尤其是在胶质母细胞瘤领域——代表了个性化肿瘤学的未来。我们的投资体现了我们坚定支持那些致力于提升患者护理水平的全球领导者。”

We look forward to seeing the immediate impact of our automated platform integration as Kiyatec scales its commercial operations and moves swiftly to bring vital functional diagnostic information to patients with brain, lung, breast and gynecological cancers.'.

我们期待看到我们的自动化平台整合带来的直接影响，因为Kiyatec扩展其商业运营，并迅速为脑癌、肺癌、乳腺癌和妇科癌症患者提供重要的功能诊断信息。

The investment will primarily be utilized to fund the company’s commercial expansion, AI tool integration and further drive clinical evidence generation necessary for broad reimbursement coverage.

这笔投资将主要用于资助公司的商业扩展、人工智能工具的整合，并进一步推动广泛的报销覆盖所需的临床证据生成。

About Kiyatec

关于Kiyatec

Kiyatec is a functional diagnostics company serving clinicians and drug developers with its proprietary 3D Predict™ platform, which physically models a patient's tumor microenvironment in 3D to predict response to cancer therapies. The 3D Predict Glioma test is commercially available for glioblastoma and other high-grade glioma patients.

Kiyatec是一家功能诊断公司，通过其专有的3D Predict™平台为临床医生和药物开发者提供服务，该平台以三维方式物理模拟患者的肿瘤微环境，以预测对癌症治疗的反应。3D Predict Glioma测试已商业化，适用于胶质母细胞瘤和其他高级别胶质瘤患者。

For more information please visit www.kiyatec.com.

有关更多信息，请访问 www.kiyatec.com。

About MBD

关于MBD

MBD is a leading functional diagnostic company in Korea, providing commercial services for various solid cancers, beginning with lung and ovarian cancer, through its unique automated platform. By integrating the entire process from patient specimen to drug response testing and cancer therapy prediction, MBD enables accurate and personalized treatment selection.

MBD是韩国领先的机能诊断公司，通过其独特的自动化平台，为各类实体癌症（始于肺癌和卵巢癌）提供商业服务。通过整合从患者样本到药物反应测试及癌症治疗预测的整个流程，MBD实现了精准且个性化的治疗选择。

Its proprietary algorithm, CODRP™, offers high predictive accuracy and growing clinical utility in precision oncology..

其专有算法 CODRP™ 在精准肿瘤学领域提供了高预测准确性和日益增长的临床实用性。

Contacts

联系人

Eric Perreault, CEO,

埃里克·佩兰，首席执行官，

[email protected]

电子邮件地址

Bosung Ku, CEO,

具保成，首席执行官，

[email protected]

电子邮件地址

Source: businesswire.com

来源：businesswire.com